Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
The decision was supported by positive data from two phase 3 trials in which Encelto (revakinagene taroretcel-lwey) slowed the loss of macular photoreceptors in patients with macular telangiectasia (MacTel) over 24 months. As Healio previously reported, the cell therapy, previously known as NT-501, met the primary outcomes of both phase 3